🟢 Vera Therapeutics is trading 6% up today in pre-market after narrower-than-expected Q2 loss

Vera Therapeutics is trading 5.65% up at $32.00 after its August 10, 2026, second-quarter update highlighted a narrower-than-expected $1.52-per-share loss.

• Cash was $499.2 million, and TRUTAKNA commercialization began.
• The company reiterated pivotal third-quarter eGFR analysis supporting a supplemental filing planned for the fourth quarter; the release identifies TRUTAKNA’s accelerated FDA approval and commercial transition as key developments.
• The move follows two consecutive declines and outpaced the modestly positive broader market; confidence is medium because direct pre-market attribution is limited.